文献速递类风湿关节炎

类风湿关节炎合并慢性肾脏病患者生物制剂与靶向合成DMARDs的疗效与持续性

Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2026-04-22

BACKGROUND: Chronic kidney disease is a common comorbidity of rheumatoid arthritis. Because there has been scarce and conflicting evidence on the use of biological and targeted synthetic therapy in patients with rheumatoid arthritis and chronic kidney disease, we aimed to examine…

要点

  • 该高风险人群需制定个体化治疗策略。

核心结论

  • 尽管生物/靶向合成DMARDs总体耐受且有效,eGFR降低的RA患者达到CDAI缓解的可能性更低。

研究设计与样本

  • 多中心前瞻性队列研究,使用CorEvitas RA注册库数据,纳入160家美国风湿科 practice 的RA患者。
  • 纳入CDAI>10且起始TNF抑制剂、CTLA4免疫球蛋白、IL-6抑制剂、B细胞清除治疗或JAK抑制剂的患者。

主要发现

  • 2001年10月1日至2023年12月31日共识别12 123次治疗起始(9 601例患者),随访51 931人年。

关键数值与推荐

  • CDAI评分>10定义为中高疾病活动度。
  • 主要结局为CDAI缓解。

临床怎么用

  • 对RA合并eGFR降低患者,应知晓其达到CDAI缓解的可能性较低,需考虑个体化治疗策略。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease is a common comorbidity of rheumatoid arthritis. Because there has been scarce and conflicting evidence on the use of biological and targeted synthetic therapy in patients with rheumatoid arthritis and chronic kidney disease, we aimed to examine the effectiveness and persistence of biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for patients with rheumatoid arthritis and chronic kidney disease. METHODS: This multicentre, prospective cohort study used data from the CorEvitas Rheumatoid Arthritis registry on patients with rheumatoid arthritis who initiated each type of biological and targeted synthetic DMARD (TNF inhibitors, CTLA4 immunoglobulin, IL-6 inhibitors, B-cell depletion therapy, and JAK inhibitors) recruited from 160 rheumatology practices in the USA. Patients were required to have moderate or high disease activity according to the Clinical Disease Activity Index (CDAI; score >10). Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) of less than 60 mL/min per 1·73 m2 at biological or targeted synthetic DMARD initiation. The primary outcome was the attainment of remission according to CDAI score. Propensity scores were used for overlap weighting to improve the balance of characteristics for patients with and without reduced eGFR. Cox regressions estimated the unadjusted and adjusted hazard ratio (HR) of reduced eGFR for CDAI-based remission. People with lived experience of rheumatoid arthritis were not involved in the study design or conduct. FINDINGS: Between Oct 1, 2001, and Dec 31, 2023, 12 123 biological and targeted synthetic DMARD treatment initiations in 9601 patients with rheumatoid arthritis, with 51 931 person-years of follow-up, were identified. Of 12 123 eligible biological and targeted synthetic DMARD treatment initiations, 10 857 (89·6%) were in patients with preserved eGFR and 1266 (10·4%) were in patients with reduced eGFR. Across both groups, median age was 59·0 years (IQR 50·0-67·0), 9720 (80·2%) of 12 123 treatment initiations were in female patients and 2403 (19·8%) were in male patients, and 9908 (81·7%) were in non-Hispanic White patients. 3025 (27·9%) of 10 857 treatment initiations in patients with preserved eGFR resulted in CDAI-based remission versus 246 (19·4%) of 1266 treatment initiations in patients with reduced eGFR. Reduced eGFR was associated with a lower likelihood of attaining CDAI-based remission (unadjusted HR 0·71 [95% CI 0·62-0·82], adjusted HR 0·76 [0·66-0·88]) compared with preserved eGFR. INTERPRETATION: Although biological and targeted synthetic DMARDs are generally well tolerated and effective options, patients with rheumatoid arthritis and reduced eGFR have lower likelihood of attaining remission. Tailored treatment strategies for this high-risk population should be established. FUNDING: National Institute of Arthritis and Musculoskeletal and Skin Diseases.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fukui S, Ørbo HS, Tedeschi SK, et al. Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study. Lancet Rheumatol. 2026. PMID: 42034110. doi:10.1016/S2665-9913(26)00046-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。